Varón con HIV+, lumbalgia e insuficiencia renal aguda (IRA)
Citas
Álvarez Lipea R, Marína FM, Abascal Ruizc JA. Berni A, Dourdil V, Palomera L. Tratamiento de la ira secundaria a mieloma múltiple con filtro de high cut-off. Dial Traspl. 2013;34(1):36-40.
Atta MG, Deray G, Lucas GM. Antiretroviral nephrotoxicities. Semin Nephrol. 2008 Nov;28(6):563-75.
De Alarcón Jiménez RM, Roca Meroño S, Álvarez Fernández GM, García Hernández MA, Navarro Parreño MJ, Jimeno Griñó C, et al. Recuperación parcial de la función renal tras trasplante autólogo en paciente con enfermedad renal crónica y mieloma múltiple. Nefrología (Madr.) 2011;31(2):238-40.
Campos ML, Barbosa de Carvalho NM, Martín-Reyes G. Valor del ensayo de las cadenas ligeras libres en suero para los pacientes de gammapatías
monoclonales e insuficiencia renal. Nefrologia (Madr.) 2012;32(1):15-9.
Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Curr Cancer Drug Targets. 2011;11(3):239-53.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976-84.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73.
García Pérez A, Ramos AM, Petkov V, Albalate M, Caramelo C, López Lorenzo JL, et al. Insuficiencia renal por enfermedad de depósito de cadenas ligeras. Nefrologia (Madr.) 2008;28(2):212-5.
Gomis A, Oliva L, Muriel A, Quereda C. ¿Se asocia la rápida reducción de las cadenas ligeras en suero con la recuperación renal en el riñón de mieloma? Nefrología Supl. Extraord. 2011;2(7):30-3.
Grima DT, Airia P, Attard C, Hutchison CA. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin. 2011;27(2):383-91.
Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP, et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012;8(4):234-43.
Hutchison C, Bridoux F, Fermand JP. Renal improvement in myeloma with plasma exchange. N Engl J Med. 2011 Sep 15;365(11):1061; author reply 1062.
Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18(3):886-95.
Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. 2008;9:55.
Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563-73.
Kalim S, Szczech LA, Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol. 2008;28(6):556-62.
Kelly MD, Gibson A, Bartlett H, Rowling D, Patten J. Tenofovir-associated proteinuria. AIDS. 2013;27(3):479-81.
Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, De Meester J, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant. 2010;25(4):1200-6.
Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28(6):513-22.
